Zydus Cadila in South Africa

Zydus Cadila’s Strategic Expansion in South Africa

Johannesburg, South Africa – July 27, 2025

Zydus Cadila, a leading Indian multinational pharmaceutical company, has been actively expanding its footprint in the South African pharmaceutical market. In 2008, the company acquired a 70% stake in Simayla Pharmaceuticals, a prominent South African generic drug manufacturer. By 2013, Zydus Cadila had increased its ownership to 100%, integrating Simayla fully into its operations. (business-standard.com)

This strategic acquisition enabled Zydus Cadila to enhance its presence in the cardiovascular, anti-infective, respiratory, gastrointestinal, and women’s healthcare segments within South Africa. The integration of Simayla’s portfolio has been instrumental in addressing the growing demand for affordable and high-quality generic medications in the region.

In 2013, Zydus Cadila expressed optimism about the South African market, highlighting its potential for growth. The company aimed to leverage its expanded operations to contribute significantly to the local healthcare sector. (business-standard.com)

As of July 2025, Zydus Cadila continues to strengthen its position in South Africa, focusing on providing a diverse range of pharmaceutical products to meet the evolving healthcare needs of the population. The company’s commitment to ethical healthcare practices and long-term growth strategies underscores its dedication to improving access to essential medicines in the region.

Through its sustained investments and strategic initiatives, Zydus Cadila remains a key player in South Africa’s pharmaceutical industry, contributing to the advancement of healthcare standards and the well-being of its citizens.